• Explore /
  • Poster
  • / A randomized, triple negative breast cancer enrolling trial to confirm molecular profiling improves survival (ARTEMIS).

A randomized, triple negative breast cancer enrolling trial to confirm molecular profiling improves survival (ARTEMIS).

Abstract Poster

Authors

null

Clinton Yam

The University of Texas MD Anderson Cancer Center, Houston, TX

Clinton Yam , Kenneth R. Hess , Jennifer Keating Litton , Wei Tse Yang , Helen Piwnica-Worms , Elizabeth Ann Mittendorf , Naoto T. Ueno , Bora Lim , Rashmi Krishna Murthy , Senthil Kumar Damodaran , Thorunn Helgason , Lei Huo , Alastair Mark Thompson , Michael Gilcrease , Lumarie Santiago , Rosalind P Candelaria , Gaiane Rauch , Beatriz Adrada , William Fraser Symmans , Stacy L. Moulder

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer—Local/Regional/Adjuvant

Track

Breast Cancer

Sub Track

Neoadjuvant Therapy

Clinical Trial Registration Number

NCT02276443

Citation

J Clin Oncol 35, 2017 (suppl; abstr TPS590)

DOI

10.1200/JCO.2017.35.15_suppl.TPS590

Abstract #

TPS590

Poster Bd #

188a

Abstract Disclosures

Similar Posters

First Author: Sahil Seth

Poster

2019 ASCO Annual Meeting

Evaluation of predictive biomarkers for AR therapy and to identify the LAR subtype of TNBC.

Evaluation of predictive biomarkers for AR therapy and to identify the LAR subtype of TNBC.

First Author: Sahil Seth

First Author: Stacy L. Moulder

First Author: Nour Abuhadra